Acumen Q4 2023 Earnings Report
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $52.4 million for the year ended December 31, 2023. The company's cash, cash equivalents, and marketable securities totaled $306.1 million as of December 31, 2023, which is expected to support clinical and operational activities into the first half of 2027. The company is focused on advancing the clinical development of sabirnetug and expects to initiate a Phase 2 study in the first half of this year.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease is expected in the first half of 2024.
Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug is expected in mid-2024.
Cash, cash equivalents and marketable securities totaled $306.1 million as of December 31, 2023, expected to support current clinical and operational activities into the first half of 2027.
The company presented fluid biomarker and target engagement analyses from Phase 1 INTERCEPT-AD study in AD at the International Conference on Alzheimer’s and Parkinson’s diseases (AD/PD).
Acumen
Acumen
Forward Guidance
Acumen Pharmaceuticals anticipates initiating a Phase 2 study, ALTITUDE-AD, in the first half of 2024 to investigate the clinical efficacy, safety, and tolerability of sabirnetug for the treatment of early Alzheimer’s disease. The company also expects to initiate a Phase 1 bioavailability study to support a subcutaneous dosing option of sabirnetug in mid-2024.
Positive Outlook
- Initiate Phase 2 study, ALTITUDE-AD, in H1 2024.
- Investigate clinical efficacy, safety and tolerability of sabirnetug.
- Treatment of early Alzheimer’s disease.
- Initiate Phase 1 bioavailability study in mid-2024.
- Support subcutaneous dosing option of sabirnetug.